Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia

[11] Quist-Paulsen P(1983)Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308 1005-1009

[12] Vaitkeviciene G(1998)Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study Blood 92 3569-3577

[13] Vettenranta K(1986)Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations Clin Pharmacol Ther 40 287-292

[14] Asberg A(1986)Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia Clin Pharmacol Ther 40 604-609

[15] Frandsen TL(2007)Comparative in vitro studies on different 6-mercaptopurine formulations for use in children Paediatr Perinatal Drug Ther 8 1-1613

[16] Marquart HV(2012)A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia J Clin Pharmacol 52 1610-259

[17] Madsen HO(2014)Complying with the European Clinical Trials directive while surviving the administrative pressure—an alternative approach to toxicity registration in a cancer trial Eur J Cancer 50 251-412

[18] Noren-Nystrom U(2013)Risk group assignment differs for children and adults 1–45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol Eur J Haematol 90 404-1152

[19] Schmiegelow K(2005)The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29–30, 2005 Leukemia 19 1145-2111

[20] Hunger SP(2016)Maintenance therapy of childhood acute lymphoblastic leukemia revisited—should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Pediatr Blood Cancer 63 2104-21

[11] Quist-Paulsen P(1983)Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308 1005-1009

[12] Vaitkeviciene G(1998)Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study Blood 92 3569-3577

[13] Vettenranta K(1986)Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations Clin Pharmacol Ther 40 287-292

[14] Asberg A(1986)Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia Clin Pharmacol Ther 40 604-609

[15] Frandsen TL(2007)Comparative in vitro studies on different 6-mercaptopurine formulations for use in children Paediatr Perinatal Drug Ther 8 1-1613

[16] Marquart HV(2012)A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia J Clin Pharmacol 52 1610-259

[17] Madsen HO(2014)Complying with the European Clinical Trials directive while surviving the administrative pressure—an alternative approach to toxicity registration in a cancer trial Eur J Cancer 50 251-412

[18] Noren-Nystrom U(2013)Risk group assignment differs for children and adults 1–45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol Eur J Haematol 90 404-1152

[19] Schmiegelow K(2005)The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29–30, 2005 Leukemia 19 1145-2111

[20] Hunger SP(2016)Maintenance therapy of childhood acute lymphoblastic leukemia revisited—should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Pediatr Blood Cancer 63 2104-21